Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
9617774
Reference Type
Journal Article
Subtype
Review
Title
Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management
Author(s)
Naji, M; Hodolic, M; El-Refai, S; Khan, S; Marzola, MC; Rubello, D; Al-Nahhas, A
Year
2010
Is Peer Reviewed?
Yes
Journal
Journal of Endocrinological Investigation
ISSN:
0391-4097
EISSN:
1720-8386
Volume
33
Issue
1
Page Numbers
54-60
Language
English
PMID
19820296
DOI
10.1007/BF03346550
Abstract
Endocrine tumors comprise a range of benign and malignant conditions that produce a spectrum of clinical symptoms and signs depending on the specific hormones they produce. The symptoms and presentations of these tumors are often independent of their size and location. Because of their expression of cell membrane receptors or production of specific types of hormones or peptides, endocrine tumors can be identified with functional radionuclide imaging much more readily compared to standard cross-sectional imaging. In recent years, 18F-fluoro-deoxy- D-glucose positron emission tomography (18F-FDG-PET) has emerged as a useful tool for diagnosing and assessing many tumors. In this review we describe how PET, using 18F-FDG and other radiopharmaceuticals can be useful in the diagnosis and management of a wide range of endocrine tumors.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity